Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colin C Collins

Showing results (51-60 of 95) with videos related to

Pageof 10
Sort By:
Cancer Medicine|June 16, 2018
Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancerStephen Yiu Chuen Choi, Susan L Ettinger, Dong Lin, et al.
BMC Bioinformatics|March 21, 2014
ShatterProof: operational detection and quantification of chromothripsisShaylan K Govind, Amin Zia, Pablo H Hennings-Yeomans, et al.
Cancer Science|May 7, 2021
Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13Kosuke Okasho, Kei Mizuno, Tomohiro Fukui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2015
Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growthYoshiaki Yamamoto, Yohann Loriot, Eliana Beraldi, et al.
Genome Biology|January 28, 2016
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patientsNada Lallous, Stanislav V Volik, Shannon Awrey, et al.
Oncotarget|May 3, 2017
Metabolic heterogeneity signature of primary treatment-naïve prostate cancerDong Lin, Susan L Ettinger, Sifeng Qu, et al.
International Journal of Cancer|May 25, 2019
Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinomaMohammed Alshalalfa, Yang Liu, Alexander W Wyatt, et al.
Oncotarget|March 26, 2016
The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cellsMark P Labrecque, Mandeep K Takhar, Rebecca Nason, et al.
European Urology|December 15, 2015
The Proteome of Primary Prostate CancerDiego Iglesias-Gato, Pernilla Wikström, Stefka Tyanova, et al.
JAMA Oncology|May 6, 2016
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate CancerAlexander W Wyatt, Arun A Azad, Stanislav V Volik, et al.
Pageof 10

Showing results (51-60 of 95) with videos related to

Sort By:
Pageof 10
Cancer Medicine|June 16, 2018
Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancerStephen Yiu Chuen Choi, Susan L Ettinger, Dong Lin, et al.
BMC Bioinformatics|March 21, 2014
ShatterProof: operational detection and quantification of chromothripsisShaylan K Govind, Amin Zia, Pablo H Hennings-Yeomans, et al.
Cancer Science|May 7, 2021
Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13Kosuke Okasho, Kei Mizuno, Tomohiro Fukui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2015
Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growthYoshiaki Yamamoto, Yohann Loriot, Eliana Beraldi, et al.
Genome Biology|January 28, 2016
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patientsNada Lallous, Stanislav V Volik, Shannon Awrey, et al.
Oncotarget|May 3, 2017
Metabolic heterogeneity signature of primary treatment-naïve prostate cancerDong Lin, Susan L Ettinger, Sifeng Qu, et al.
International Journal of Cancer|May 25, 2019
Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinomaMohammed Alshalalfa, Yang Liu, Alexander W Wyatt, et al.
Oncotarget|March 26, 2016
The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cellsMark P Labrecque, Mandeep K Takhar, Rebecca Nason, et al.
European Urology|December 15, 2015
The Proteome of Primary Prostate CancerDiego Iglesias-Gato, Pernilla Wikström, Stefka Tyanova, et al.
JAMA Oncology|May 6, 2016
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate CancerAlexander W Wyatt, Arun A Azad, Stanislav V Volik, et al.
Pageof 10